DOCSLIB.ORG

Leveraging the Perrigo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leveraging the Perrigo ® 2014 ANNUAL REPORT AdvantageLeveraging the Perrigo Corporate Profile From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world’s largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo’s mission is to offer uncompromised Quality Affordable Healthcare Products®, and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Contents 1 Financial Highlights 2 Shareholder Letter 10 Consumer Healthcare 12 Nutritionals 16 Rx Pharmaceuticals 18 API 18 Specialty Sciences 19 e-Commerce 20 Supply Chain 22 Shareholder Information 24 Financial Reconciliation Financial Highlights Year ended Financial Results - Reported (GAAP) (1) June 29, 2013 June 28, 2014 % Change In millions, except per share amounts Net Sales $ 3,539.8 $ 4,060.8 15% Operating Income $ 679.1 $ 567.0 -17% Net Income $ 441.9 $ 205.3 -54% Diluted EPS $ 4.68 $ 1.77 -62% Average Diluted Shares Outstanding 94.5 115.6 22% Year ended Financial Results - Adjusted (Non-GAAP) June 29, 2013 (2) June 28, 2014 (2) % Change In millions, except per share amounts Net Sales $ 3,539.8 $ 4,060.8 15% Adjusted Operating Income $ 805.3 $ 1,029.2 28% Adjusted Net Income $ 529.7 $ 739.5 40% Adjusted Diluted EPS $ 5.61 $ 6.39 14% Average Diluted Shares Outstanding 94.5 115.6 22% $4,060.8 $3,539.8 115.6 $1,029.2 $6.39 94.5 $805.3 $5.61 $739.5 $529.7 2013 2014 2013 2014 2013 2014 2013 2014 2013 2014 Net Sales Adjusted Operating Adjusted Net Income Adjusted Diluted EPS Average Diluted (In millions) Income (In millions) Shares Outstanding (In millions) (In millions) (1) See Item 7 in the Form 10-K report for a discussion of results of operations. (2) See reconciliation of non-GAAP financial measures on page 24. We have excluded certain items when monitoring and evaluating Perrigo Company plc’s ongoing financial results because we believe this provides important insight into the Company’s ongoing core business operations on a normalized basis. 1 Dear Fellow Shareholders: This has been an extraordinary year for our company. In past letters to share- holders, I described Perrigo as the right company, in the right place, at the right time. That description not only remained true in fiscal year 2014, but it also makes more sense going forward given our relentless emphasis on our vision, our guiding principles and on our unique and sustainable business model. Our Vision Our vision at Perrigo Company plc is to be an undisputed leader in providing the world with Quality Affordable Healthcare Products®. During fiscal 2014, we made even more progress in fulfilling that dream. Our global team delivered record revenue of $4.06 billion, record adjusted earnings and record adjusted gross and operating margins in fiscal 2014. The team also delivered a 15% increase in sales over fiscal 2013, driven by a balanced mix of organic growth, sales of products from companies we acquired in fiscal 2013 and sales of new products. Notably, in the third quarter, Perrigo crossed the $1 billion mark in quarterly revenue for the first time, despite a weak retail environment and relatively light cough, cold and flu season. Fiscal 2014 was also noteworthy as the eighth consecutive year in which the Perrigo team increased revenue, operating cash flow and adjusted operating margin. These achievements further demonstrate that the durable business model of our 127-year-old company continues to yield opportunities for long-term growth. Driving Growth While we are obviously proud of our fiscal 2014 results, we have no intention to “rest on our laurels” or to lose our focus. To the contrary, we continue to run hard and remain bullish about our business going forward. Our business strategy enables Perrigo to consistently deliver outstanding results, well-balanced between organic and inorganic contributions. From 2008 to 2014, this strategy led Perrigo to achieve a net sales compound annual growth rate of 16 percent. That impressive number consisted of an equally impressive growth of 8 percent for organic sales and 8 percent for inorganic sales. Looking to the future, we believe that global demographic and economic megatrends will continue to provide fertile soil for future growth at Perrigo. These favorable megatrends include aging populations that are expected to require more healthcare products; the increasing number of drugs switching from prescription (Rx) to over-the-counter (OTC) status; and movement from national brand to store brand in the OTC marketplace. 2 New Product Pipeline / Innovation – 160 Filings Awaiting Approval Stock Performance $150 428% $100 $50 Total shareholder return in 5 years $0 6/29/2009 2010 2011 2012 2013 2014 6/28/2014 3 This is a very exciting time for us at Perrigo. Through disciplined acquisitions, we have the potential to expand into dynamic new categories, geographies and segments. Over the past seven years, we completed 19 merger and acquisition (M&A) transactions, which expanded our business on three continents, extended our business into three 80Yrs new categories and doubled our work force. Elan Pharmaceuticals Acquisition Average life expectancy has Our acquisition of Elan Pharmaceuticals in December 2013 transformed our ability increased by 10 years to to drive more growth to Perrigo’s bottom line by expanding our global capabilities and 80 years since 1960. competencies. It is our largest and most exciting venture to date. We acquired Elan for approximately $9.5 billion in cash and stock and re-domiciled our headquarters in Dublin, Ireland. This acquisition immediately doubled our market capitalization, strengthened our position as a truly differentiated business and opened a gateway for further international expansion. It also generated an attractive revenue stream from an important multiple sclerosis drug. Our Quality Affordable Healthcare Products® One of the most gratifying indicators of our growth and success is the widespread global use of our products. We own leadership positions in consumer healthcare, infant formula and animal health store brands, as well as in generic prescription extended topical products. Every second of every day, approximately 1,600 people worldwide use a product made by Perrigo. Another rewarding aspect of our success is the opportunity it provides to make a real difference in people’s lives. The fact that our products treat illnesses, help people feel better and stay healthy, nourish infants and toddlers and care for pets – all while saving them money – inspires Perrigo employees to remain focused on expanding our portfolio, developing new products, partnering with our retail customers and efficiently managing the complexity of our supply chain and manufacturing operations. Speaking of new products, they remain essential components of Perrigo’s growth and our leadership position. In fiscal 2014, Perrigo manufactured 47 billion oral solid 4 doses and approximately 3 billion liquid/cream doses in more than 3,000 formula- tions and approximately 18,000 stock keeping units (SKUs). We also launched many new products across all segments during the fiscal year at a rate of nearly two new products each week. Examples include the generic equivalent of Temodar® 5Pillars (temozolomide) for the treatment of cancer and Prandin® Tablets (repaglinide tablets) for Type 2 diabetes. Similarly, the conversion of our infant formula packaging to the � Quality new SmarTubTM was well received by our retail customers as it generated strong � Customer Service sales, improved shelf presence and additional consumer loyalty. � Innovation � Cost Effectiveness � People Our Foundation of Five Pillars and Core Values While we are proud of the many metrics that can be used to establish Perrigo’s success over the years, we are most proud of the fact that we have remained grounded by our Five Pillars: Quality, Customer Service, Innovation, Cost Effectiveness and People. Our Core Values of Integrity, Respect and Responsibility guide us and, together with the Pillars, remain the foundation of our growth and provide clear, consistent guidance to our employees on how we run our business. Let me elaborate on this. We understand that if our products are not quality products, then neither our customers nor end consumers will purchase them. We also take Quality seriously because we know that our products are used by loved ones, friends and neighbors. We are committed to Customer Service as we can best maintain sales growth and positive relationships with our retail partners by consistently delivering on our promises to them. Our commitment to Innovation is vividly demonstrated by the 160 new product filings awaiting regulatory approval, the 280 projects under development and the 6,000 SKUs in conversions. Cost Effectiveness continues to drive our focus on supply chain and business process efficiencies to ensure that we are as productive and competitive as possible in the global marketplace. Finally, over 10,000 Perrigo People around the world are excited and essential to our future growth. They are the foundation of our other Pillars – supported by an environment that stresses the importance of “doing the right thing,” consistent with Perrigo’s Core Values and Code of Conduct. 5 Our constant focus on the Five Pillars and Core Values, along with new product launches and disciplined M&A, has driven our strong topline growth, adjusted gross margin expansion and robust cash flow generation. Our Unique, Sustainable, Competitive Business Model Although we have had an impressive track record at Perrigo over the last several fiscal years, I am equally excited and optimistic about our future.
Load more

Recommended publications
  • Understanding the FTC's Monetary Equitable Remedies Under Section
    Understanding the FTC’s monetary equitable remedies under Section 13(b) for antitrust violations By Gerald A. Stein, American Bar Association — Fall 2019 Until recently the Federal Trade Commission’s ability to seek monetary equitable remedies (particularly disgorgement and restitution) for alleged antitrust violations— whether ongoing, impending, or stale— went virtually unchallenged. After it first gained statutory authority under Section 13(b)1 of the FTC Act to bring suit in federal district court to preliminarily enjoin conduct that “is violating, or is about to violate” the antitrust laws, the FTC successfully convinced many federal courts that Section 13(b) also impliedly allowed the FTC to seek standalone permanent injunctions and monetary equitable remedies regardless of whether a defendant’s alleged anticompetitive conduct was ongoing or completed long ago.2 The FTC brought few antitrust cases in the years following the enactment for alleged antitrust violations pursuant to Section 13(b) where the alleged of Section 13(b) in 1973, and the agency formalized its conservative anticompetitive conduct was neither ongoing nor imminent. Next, in approach in its unanimously approved 2003 Policy Statement on Monetary FTC v. Credit Bureau Center LLC,5 the Seventh Circuit vacated an award for Equitable Remedies in Competition Cases. In 2012, however, the FTC restitution in a consumer protection case based on its determination that abruptly, and without providing an opportunity for public comment, Section 13(b) authorizes only restraining orders and injunctions. And, in a withdrew its 2003 Policy Statement, asserting that it created “an overly third case that is still pending, FTC v.
    [Show full text]
  • Responding to Mylan's Inadequate Tender Offer
    Responding To Mylan’s Inadequate Tender Offer: Perrigo’s Board Recommends That You Reject the Offer and Do Not Tender September 2015 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited offer. These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 27, 2015, as well as the Company’s subsequent filings with the Securities and Exchange
    [Show full text]
  • 2020 Annual Report Products
    Products 2020 Annual Report From the CEO Dear Fellow Shareholders, Perrigo’s transformation to a pure-play Consumer Self-Care Company has come a long way LQMXVWWZRVKRUW\HDUV:HKDYHUHVWRUHGVXVWDLQDEOHWRSOLQHJURZWKGHOLYHUHGRQRXU¿QDQFLDO SURPLVHVUHFRQ¿JXUHGRXUSRUWIROLRRIEXVLQHVVHVXSGDWHGWKH,7LQIUDVWUXFWXUHDQGSURFHVVHV of the Company, expanded capacity, upgraded leadership talent, installed business intelligence capabilities, built a new product pipeline of over $500 million and re-instilled a sense of pride and energy among our 11,000 team members. Making this even more remarkable, is that we kept the WUDQVIRUPDWLRQRQWUDFNLQWKHIDFHRIWKHJOREDO&29,'SDQGHPLF,KRSH\RXDUHDVSURXGRI3HUULJR¶VJOREDOWHDP DV,DPIRUKRZWKH\ZRUNHGWRNHHSHDFKRWKHUVDIHNHSWRXUHVVHQWLDOSURGXFWVÀRZLQJDQGNHSWRXUWUDQVIRUPDWLRQ to a consumer self-care company on track through all of the personal and professional uncertainty that came their way LQ7KH\DUHKHURHV As a result of their efforts, Perrigo delivered strong net sales growth for the second year in a row in 2020 and World-wide Consumer sales reached a new record high. Equally important, the team stabilized adjusted operating income after a few years of decline even as we invested over $50 million in our business and overcame $35 million RIXQSODQQHGKHDGZLQGVGXHSULPDULO\WR&29,'UHODWHGVDIHW\FRVWVDQGEXVLQHVVLPSDFWIURPWKHZHDNFROG FRXJKDQGÀXVHDVRQUHODWHGWR&29,'¶VLPSDFWRQSXEOLFOLIH$OOLQDOOZHKDGDYHU\VWURQJ\HDU Our transformation efforts reached an essential milestone after the year closed when we announced the sale of RXU3UHVFULSWLRQ3KDUPDFHXWLFDOVEXVLQHVVWR$OWDULV&DSLWDO3DUWQHUV//&7KHWUDQVDFWLRQUHLQIRUFHVRXUDELOLW\
    [Show full text]
  • Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny from Prosecutors
    REGULATORY UPDATE REGULATORY UPDATE CONSUMER DRUGS Pediatric Rare Disease Voucher Japan Wants EMA To Stay In Digital Marketing: Health Care Brands’ Program Faces Expiration, p. 12 UK Post-Brexit, p. 15 Window Into Consumers’ Lives, p. 20 Pharma intelligence Pinkpink.pharmamedtechbi.comSheetVol. 78 / No. 38 September 19, 2016 informa Mylan NV was subpoenaed for material Pharma Pricing, Non-Profit Ties Get about the pricing of its generic doxycycline and communications with competitors. And Valeant Pharmaceuticals International Inc. is Increasing Scrutiny From Prosecutors facing several probes about its pricing and BRENDA SANDBURG [email protected] patient assistance programs (see chart, p. 5). Mylan’s doxycycline price increases were called out by Sen. Bernie Sanders, I-Vt., and Rep. Elijah Cummings, D-Md., in October 2014 when they sent letters to 14 generic drug makers about the pricing of their prod- ucts. They noted that from October 2013 to April 2014, the average price charged for a 500-count bottle of 100 mg tablets had risen from $20 to $1,829, an 8,281% increase. Mylan is now under fire for repeatedly rais- ing the price of its severe allergy treatment EpiPen (epinephrine), which has increased from about $100 for a two-pack in 2008 to more than $600. Members of Congress sent a flurry of letters to the company requesting an explanation for the price hikes. And on Sept. 6, New York Attorney Gen- Shutterstock: blvdone Shutterstock: eral Eric Schneiderman announced that his office has begun an investigation into rug makers have been unable to programs, contractual agreements with Mylan with regard to EpiPen, saying a pre- shake free of government inves- pharmacy benefit managers, support of liminary review revealed that Mylan may Dtigations of their marketing and non-profit organizations, and calculation have inserted potentially anticompetitive sales practices.
    [Show full text]
  • Plaintiff Federal Trade Commission's Post-Trial Brief
    Case 2:14-cv-05151-HB Document 403 Filed 03/23/18 Page 1 of 46 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA FEDERAL TRADE COMMISSION, Plaintiff, Case Number: 2:14-CV-5151-HB v. ABBVIE INC., et al., Defendants. PLAINTIFF FEDERAL TRADE COMMISSION’S POST-TRIAL BRIEF Armine Black Daniel S. Bradley Rebecca L. Egeland Jordy J. Hur Garth W. Huston Hannah Lamb Heather M. Johnson Thomas D. Mays Patricia M. McDermott Markus H. Meier Kara L. Monahan Lauren Peay Peter J. Taylor Matthew B. Weprin James Weingarten Attorneys for Plaintiff FEDERAL TRADE COMMISSION 600 Pennsylvania Avenue, N.W. Washington, D.C. 20580 (202) 326-2569 [email protected] Case 2:14-cv-05151-HB Document 403 Filed 03/23/18 Page 2 of 46 TABLE OF CONTENTS TABLE OF AUTHORITIES ........................................................................................................ ii KEY PERSONNEL ...................................................................................................................... vi I. Defendants’ objectively baseless lawsuits used the governmental process as an anticompetitive weapon .................................................................................................... 2 A. Defendants enjoyed substantial benefits from the collateral injuries their baseless lawsuits inflicted on Teva and Perrigo ...................................................... 3 B. The evidence at trial supports liability even under Defendants’ erroneous view that PRE requires proof that Defendants knew their lawsuits were baseless .........
    [Show full text]
  • Perrigo Board of Directors
    Perrigo Company plc Board of Directors and Their Compensation (as of August 7, 2019) Bradley A. Alford, 62, has been a director of Perrigo since February 2017. Mr. Alford joined Advent International Corporation, a global private equity firm, in 2014 as an Industry Advisor and moved to Operating Partner in March of 2016. From 2006 to 2013, Mr. Alford was Chairman and Chief Executive Officer of Nestlé USA. Mr. Alford also served as CEO and President of Nestlé Brands Company. He currently serves as a director of Avery Dennison Corporation since April 2010 and previously served as a director of Conagra Brands, Inc. from July 2015 to September 2018. Throughout his career, Mr. Alford has been focused on developing brands, initiatives to improve processes and facilitate best practices across an organization. Rolf A. Classon, 73, has been a director of Perrigo since May 2017. Mr. Classon served as Interim President and Chief Executive Officer of Hillenbrand Industries, a global diversified industrial company, from May 2005 until March 2006. From 2002 until June 2004, Mr. Classon served as Chairman of the Executive Committee of Bayer Healthcare AG, a subsidiary of Bayer AG. Mr. Classon served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon serves as a director of Fresenius Medical Care AG and Co. since May 2012, and Catalent, Inc. since July 2014. Mr. Classon also served as a director of Hill-Rom Holdings, Inc., from July 2001 to March 2018, Aerocrine AB, Stockholm from May 2013 to July 2015 and Auxilium Pharmaceuticals from July 2005 to January 2015 and served as a director of Tecan Group, Ltd.
    [Show full text]
  • View Annual Report
    A Proven Formula for Delivering Superior Shareholder Value A A Proven Formula for Delivering Superior Shareholder Value Corporate Profile From its beginnings in 1887 as a packager of generic home remedies, Perrigo Company plc, headquartered in Ireland, has grown to become the world’s largest manufacturer of over-the-counter (OTC) products and supplier of infant formulas for the store brand market, and is now a top five global OTC consumer goods and pharmaceutical company. In addition to receiving royalties from Multiple Sclerosis drug Tysabri®, the Company is also a leading provider of branded OTC products and generic extended topical prescription products. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies, primarily in North America, Europe, and Australia, as well as in other markets, including Israel and China. Perrigo 1 Fellow Shareholders, On behalf of the Perrigo management team and the over 13,000 Perrigo employees worldwide, I am extremely proud to report our tenth consecutive year of record earnings. By effectively executing our ‘Base Plus Plus Plus’ strategy, we continued our consistent track record of delivering superior shareholder returns, with a total shareholder return of over 970% since 2007. Joseph C. Papa Chairman, President, and Chief Executive Officer Over the past eight years, we have transformed Perrigo I also want to address the recent attempts by Mylan N.V. into a top five global OTC pharmaceutical company. (Mylan) to acquire Perrigo. As we have consistently In fiscal 2015, we took significant steps to build on this maintained since April, we believe Mylan’s offer platform through three highly strategic acquisitions that substantially undervalues Perrigo and is not in the best further strengthened our global scale and distribution interests of our shareholders.
    [Show full text]
  • Perrigo Annual Report 2020
    Perrigo Annual Report 2020 Form 10-K (NYSE:PRGO) Published: February 27th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-36353 Perrigo Company plc (Exact name of registrant as specified in its charter) Ireland N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74 +353 1 7094000 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, €0.001 par value PRGO New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 of Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Top 50 Companies Article Pack a Year of Surprises Shakes up Industry Top 10 Sandoz, Mylan and Teva Switch Places at the Top
    Top 50 Companies Article Pack A Year Of Surprises Shakes Up Industry Top 10 Sandoz, Mylan And Teva Switch Places At The Top Executive Summary but has vaulted to the top of our sales rankings, In an eventful year for the off-patent industry, the with its $9.37bn total for the combined generics, world’s leading generics and biosimilars players biosimilars, active pharmaceutical ingredients and have switched places in Generics Bulletin’s newly- OTC category narrowly exceeding that of Mylan, compiled global sales ranking. despite the Novartis unit seeing a 1% drop in turnover in 2019. Mylan Prepares For Viatris Merger After a year that has seen major changes for some While Mylan’s total company sales in 2019 grew by of the biggest players in the global off-patent 1% to $11.5bn, our ranking excludes from the key industry, it is perhaps no surprise that Generics category around $1.8bn of Mylan’s turnover from Bulletin’s annual ranking of the world’s top 50 respiratory and allergy brands such as EpiPen generics and biosimilars companies has reflected (epinephrine), Perforomist (formoterol) and Tobi this upheaval. (tobramycin). This year, our annual ranking of the top 50 Mylan was also a firm with very different generics and biosimilars companies is being expectations hanging over it midway through presented in three parts, and our initial look at the last year, with investors keenly anticipating the top 10 companies paints a picture that looks quite firm’s long-trailed management announcement different to the predictions that may have been of restructuring plans expected to revitalize made by industry onlookers just 12 months ago.
    [Show full text]
  • 20210316180937477 20-Xxxx
    No. 20- IN THE Supreme Court of the United States ABBVIE INC., ABBOTT LABORATORIES, UNIMED PHARMACEUTICALS LLC, AND BESINS HEALTHCARE, INC., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ON PETITION FOR A WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT PETITION FOR A WRIT OF CERTIORARI WILLIAM F. LEE SETH P. WAXMAN WILMER CUTLER PICKERING Counsel of Record HALE AND DORR LLP LEON B. GREENFIELD 60 State Street CATHERINE M.A. CARROLL Boston, MA 02109 BRITTANY BLUEITT AMADI CLAIRE H. CHUNG JEFFREY I. WEINBERGER MEDHA GARGEYA STUART N. SENATOR WILMER CUTLER PICKERING ADAM R. LAWTON HALE AND DORR LLP MUNGER, TOLLES & OLSON LLP 1875 Pennsylvania Ave., NW 350 South Grand Avenue Washington, DC 20006 Los Angeles, CA 90071 (202) 663-6000 [email protected] ELAINE J. GOLDENBERG MUNGER, TOLLES & OLSON LLP 601 Massachusetts Ave., NW Suite 500 East Washington, DC 20001 Counsel for AbbVie Inc., Abbott Laboratories, and Unimed Pharmaceuticals LLC MELINDA F. LEVITT GREGORY E. NEPPL FOLEY & LARDNER, LLP 3000 K Street, NW Washington, DC 20007 Counsel for Besins Healthcare, Inc. QUESTION PRESENTED Whether the subjective element of the “sham liti- gation” exception to Noerr-Pennington immunity may be met by an inference from a finding that a challenged lawsuit was objectively baseless, even without evidence that the antitrust defendant actually believed the suit lacked merit or was indifferent to the outcome. (i) PARTIES TO THE PROCEEDING Petitioners are AbbVie Inc., Abbott Laboratories, Unimed Pharmaceuticals LLC, and Besins Healthcare, Inc., which were defendants in the district court and appellees and cross-appellants in the court of appeals.
    [Show full text]
  • Horizon Therapeutics Plc
    Investor Presentation Horizon Therapeutics plc November 2019 HorizonTherapeutics.com Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to Horizon’s full-year 2019 net sales and adjusted EBITDA guidance; expected financial performance and operating results in future periods, including potential growth in net sales of certain of Horizon’s medicines; expected impact of refinancing transactions; expected timing of clinical trials and regulatory submissions and decisions, including related to the Biologics License Application (BLA) for teprotumumab; potential market opportunity for and benefits of Horizon’s medicines and medicine candidates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon’s ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates, such as
    [Show full text]
  • ANALYSIS of AGREEMENT CONTAINING CONSENT ORDERS to AID PUBLIC COMMENT in the Matter of Mylan N.V., File No
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT In the Matter of Mylan N.V., File No. 151-0129 The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Mylan N.V. (“Mylan”) that is designed to remedy the anticompetitive effects resulting from Mylan’s acquisition of Perrigo Company plc (“Perrigo”). Under the terms of the proposed Consent Agreement, Mylan is required to divest to Alvogen, Inc. (“Alvogen”) all of its rights and assets to the following generic pharmaceutical products: (1) acyclovir ointment; (2) bromocriptine mesylate tablets; (3) clindamycin phosphate/benzoyl peroxide gel; (4) hydromorphone hydrochloride extended release tablets; (5) liothyronine sodium tablets; (6) polyethylene glycol 3350 over-the-counter (“OTC”) oral solution packets; and (7) scopolamine extended release transdermal patches. The proposed Consent Agreement has been placed on the public record for thirty days for receipt of comments from interested persons. Comments received during this period will become part of the public record. After thirty days, the Commission will again evaluate the proposed Consent Agreement, along with the comments received, to make a final decision as to whether it should withdraw from the proposed Consent Agreement or make final the Decision and Order (“Order”). On September 14, 2015, Mylan launched a hostile tender offer to gain a controlling interest in Perrigo. The Commission alleges in its Complaint that the proposed acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C.
    [Show full text]